Advantages and limitations of renin inhibition with aliskiren;Intérêts et limites de l'inhibition de la rénine par l'aliskiren

Annales Pharmaceutiques Francaises

Volumn 69, Issue 3, 2011, Pages 142-150

  Azizi, M ^a,b,c   Frank, M ^a,b,c   Steichen, O ^a,b,c   Blanchard, A ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

Diabetes; Heart failure; Hypertension; Inhibition; Renin

Indexed keywords

ALISKIREN; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SYNTHESIS; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL PARAMETERS; PROTEINURIA; REVIEW; TREATMENT OUTCOME;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FUMARATES; HEART FAILURE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955925140     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.02.002     Document Type: Review

References (76)

1. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
2. Azizi M., Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004, 109:2492-2499.
3. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462. The Collaborative Study Group.
4. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
5. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. The GISEN Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863.
7. Ruggenenti P., Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
8. Agodoa L.Y., Appel L., Bakris G.L., Beck G., Bourgoignie J., Briggs J.P., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719-2728.
9. Jafar T.H., Schmid C.H., Landa M., Giatras I., Toto R., Remuzzi G., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73-87.
10. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
11. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
12. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
13. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
14. Inhibitor Myocardial Infarction Collaborative A.C.E Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998, 97:2202-2212.
15. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
16. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
17. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-1559.
18. Erdös E.G. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990, 16:363-370.
19. Iyer S.N., Ferrario C.M., Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998, 31:356-361.
20. Azizi M., Rousseau A., Ezan E., Guyene T.T., Michelet S., Grognet J.M., et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem-cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996, 97:839-844.
21. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234-242.
22. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998, 351:1693-1697.
23. Fisher N.D., Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities?. J Am Soc Nephrol 2005, 16:592-599.
24. Rongen G.A., Lenders J.W., Smits P., Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995, 29:6-14.
25. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.C., et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000, 7:493-504.
26. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.C., Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
27. Ganten D., Wagner J., Zeh K., Bader M., Michel J.B., Paul M., et al. Species specificity of renin kinetics in transgenic rats harboring the human renin angiotensinogen genes. Proc Natl Acad Sci U S A 1992, 89:7806-7810.
28. Azizi M., Webb R., Nussberger J., Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 2006, 24:243-256.
29. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-8.
30. Vaidyanathan S., Jarugula V., Dieterich H.A., Howard D., Dole W.P. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008, 47:515-531.
31. Zhao C., Vaidyanathan S., Yeh C.M., Maboudian M., Armin Dieterich H. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006, 45:1125-1134.
32. Vaidyanathan S., Bigler H., Yeh C., Bizot M.N., Dieterich H.A., Howard D., Dole W.P. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007, 46:661-675.
33. Tapaninen T., Neuvonen P.J., Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010, 88:339-342.
34. Vaidyanathan S., Maboudian M., Warren V., Yeh C.M., Dieterich H.A., Howard D., et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008, 24:2313-2326.
35. Azizi M., Menard J., Bissery A., Guyenne T.T., Bura-Riviere A., Vaidyanathan S., et al. Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II-Renin Feedback Interruption. J Am Soc Nephrol 2004, 15:3126-3133.
36. Okunishi H., Miyazaki M., Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984, 2:277-284.
37. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990, 265:22348-22357.
38. Carey R.M., Wang Z.Q., Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000, 35:155-163.
39. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004, 109:8-13.
40. Reudelhuber T.L. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005, 46:1261-1262.
41. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47:25-49.
42. Nguyen G., Delarue F., Berrou J., Rondeau E., Sraer J.D. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897-1903.
43. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
44. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
45. Feldt S., Batenburg W.W., Mazak I., Maschke U., Wellner M., Kvakan H., et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008, 51:682-688.
46. Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52:130-136.
47. Luetscher J.A., Kraemer F.B., Wilson D.M., Schwartz H.C., Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985, 312:1412-1417.
48. Deinum J., Ronn B., Mathiesen E., Derkx F.H., Hop W.C., Schalekamp M.A. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999, 42:1006-1010.
49. Ichihara A., Kaneshiro Y., Suzuki F. Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin Investig Drugs 2006, 15:1137-1139.
50. Cousin C., Bracquart D., Contrepas A., Corvol P., Muller L., Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009, 53:1077-1082.
51. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
52. Oh B.H., Mitchell J., Herron J.R., Chung J., Khan M., Keefe D.L. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49:1157-1163.
53. Schmieder R.E., Philipp T., Guerediaga J., Gorostidi M., Smith B., Weissbach N., et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009, 119:417-425.
54. Andersen K., Weinberger M.H., Egan B., Constance C.M., Ali M.A., Jin J., et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008, 26:589-599.
55. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221-229.
56. Musini V.M., Fortin P.M., Bassett K., Wright J.M. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens 2009, 23:495-502.
57. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H., Matrisciano-Dimichino L., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
58. Littlejohn T.W., 3rd, Trenkwalder P., Hollanders G., Zhao Y., Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009, 25:951-959.
59. Jordan J., Engeli S., Boye S.W., Le Breton S., Keefe D.L. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
60. O'Brien E., Barton J., Nussberger J., Mulcahy D., Jensen C., Dicker P., et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49:276-284.
61. van Paassen P., de Zeeuw D., Navis G., de Jong P.E. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000, 15:637-643.
62. Cherney D.Z., Lai V., Scholey J.W., Miller J.A., Zinman B., Reich H.N. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010, 33:361-365.
63. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C.D., Schalkwijk C., et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010, 53:1576-1580.
64. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C.D., Schalkwijk C., et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32:1873-1879.
65. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
66. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010;33:2304-9.
67. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
68. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
69. McMurray J.J.V., Pitt B., Latini R., Maggioni A.P., Solomon S.D., Keefe D.K., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17-24.
70. Sever P.S., Gradman A.H., Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009, 10:65-76.
71. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation.$ 2009, 119:530-537.
72. Solomon SD. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction: ASPIRE. Late breaking clinical science. Paper presented at: American College of Cardiology, 2010; Atlanta.
73. Stanton A., Jensen C., Nussberger J., O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137-1143.
74. Livio F., Ivanyuk A., Biollaz J., Rothuizen L., Buclin T. [Pharmacovigilance update]. Rev Med Suisse 2010, 6:128-131.
75. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
76. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.